Web Analytics
หุ้น AXSM (NASDAQ) | AXSOME THERAPEUTICS INC – วิเคราะห์โดย Deepscope
MARKET

Select Market Data Region

AXSM — AXSOME THERAPEUTICS INC (Healthcare >> Biotechnology)

AXSM FAQ

What is AXSM's ROE?

AXSOME THERAPEUTICS INC reports a Return on Equity (ROE) of -344.96%.

What is AXSM's dividend yield?

AXSOME THERAPEUTICS INC offers a dividend yield of 0.00%.

What is AXSM's Deepscope Quality Score?

Deepscope rates AXSM's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy AXSM?

Deepscope's AI Timing Score for AXSM is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does AXSM belong to?

AXSOME THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Stock Check   *ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.*
(Price: 2026-06-03 | FS: 2026-03-31)

AXSM

AXSOME THERAPEUTICS INC
USD 233.49
11.33 (5.10%) Day Change
3.45
D/E
-345.0%
ROE
-26.4%
ROA
0.00%
Div Yield
USD 233.49
Price
11.33 (5.10%)
Day Change
NEWS SCORE: 98

AXSM มีคุณภาพโดยรวมไม่ดี ( คะแนนปัจจัยพื้นฐาน = 38) แต่ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

38

QUALITY

Signal
UNDERPERFORM
Signal Description
Company financial health is Not Good
Reason
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ลดลงอย่างมีนัยยะสำคัญ
อัตราเร่งของการเติบโตของอัตราผลตอบแทนสินทรัพย์ (ROA) ต่ำกว่าเกณฑ์
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์
อัตรากำไรสุทธิในอดีต ค่อนข้างต่ำ

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร ยังไม่ดีนัก , ...

ปัจจัยทางคุณภาพ 42%
X
X
X
X
  In Recommendations? In "Invest - GROWTH" Section
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 98
  Magic Formula Rank by ROA
N/A
  Magic Formula Rank by ROE
N/A
  Magic Formula Rank by ROIC
N/A
  Price 233.49
  PBV / Sector
209.43 / 4.48
  Earning Per Share -3.85
  PE / Sector
N/A / 16.68
  PEG or PE/Growth / Sector
N/A / 0.53
  Average 1M Daily Value
136.71 M
GREAT
  Average 1W Daily Value
144.78 M
GREAT
ปัจจัยทางเทคนิค 57%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
สุขภาพทางการเงิน 37%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
ประสิทธิภาพการทำกำไร 54%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
-26.59 / 450.37
  NPM Average (%) / Sector
-118.43 / -1,506.30
  NPM Change Average (%) / Sector
-40.23 / 4,941.44
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
-26.39 / 30.83
  ROA Average (%) / Sector
-40.12 / -347.12
  ROA Change Average (%) / Sector
-12.95 / 5,126.35
  ROE (%) / Sector
-344.96 / -3.04
  ROE Average (%) / Sector
-270.45 / 40.76
  ROE Change Average (%) / Sector
70.73 / 2,110.63
GREAT
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
ผลตอบแทนต่อผู้ถือหุ้น 4%
X
  Dividend (%) / Sector
N/A / 0.05
  Dividend Average (%) / Sector
N/A / 16.49
  Dividend Change Average (%) / Sector
N/A / 5.25
รายละเอียดการจดทะเบียน
X
  Analyze Date 2026-06-04 09:23:39
  Symbol AXSM
  Name AXSOME THERAPEUTICS INC
  Sector Healthcare >> Biotechnology
  Market NASDAQ
  Listed Shares 51.46 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 11,432.30 / 8,483.11
ข่าว, ประมาณการ, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: One World Trade Center, New York, NY, United States, 10007

Phone: 212 332 3241

Website: https://www.axsome.com

Employees: 1,220

Sector: Healthcare >> Biotechnology

Description: Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

ME vs SECTOR Healthcare >> Biotechnology

AXSM (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
AXSM
AXSM
USD 233.49 (5.10%)
+ Watch + Port Chart